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Abstract
One of the major challenges in management of spinal cord injury (SCI) is that the assessment of injury severity is often
imprecise. Identification of reliable, easily quantifiable biomarkers that delineate the severity of the initial injury and that
have prognostic value for the degree of functional recovery would significantly aid the clinician in the choice of potential
treatments. To find such biomarkers we performed quantitative liquid chromatography-mass spectrometry (LC-MS/MS)
analyses of cerebrospinal fluid (CSF) collected from rats 24 h after either a moderate or severe SCI. We identified a panel of
42 putative biomarkers of SCI, 10 of which represent potential biomarkers of SCI severity. Three of the candidate biomarkers,
Ywhaz, Itih4, and Gpx3 were also validated by Western blot in a biological replicate of the injury. The putative biomarkers
identified in this study may potentially be a valuable tool in the assessment of the extent of spinal cord damage.
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Introduction
It is estimated that over 30,000 people in Canada, and
approximately ten times that many in the USA, are living with
spinal cord injury (SCI), and more than 1,000 and 11,000 new
cases occur annually in Canada and the USA, respectively (http://
rickhansenregistry.org; https://www.nscisc.uab.edu).
Improvements in the medical, surgical, and rehabilitative care
have dramatically extended the lifespan and increased the quality
of life of individuals with acute and chronic SCI, but much
remains to be improved in restoring function for individuals with
SCI. Little can be done about the primary mechanical damage to
the spinal cord that occurs on impact. However, most spinal cord
injuries are anatomically incomplete and the secondary paren-
chymal damage contributes significantly to the final extent of
neural damage and ultimately to the extent of the long term
disability [1,2,3]. Due to its prolonged nature, this secondary
injury is amenable to treatment, and a number of candidate
neuroprotective interventions that may potentially halt or
attenuate the secondary damage have been developed [4]. The
severity of the initial injury likely plays a significant role in
determining the nature and amplitude of the secondary response
and thus the appropriate interventions. However, the current
clinical measures for characterizing injury severity are based on
functional tests that cannot be relied upon immediately following
injury because they are often compromised by shock, other
attendant injuries and drugs or alcohol.
Biomarkers are objectively quantifiable biological characteristics
and represent a very attractive and unbiased tool for assessing SCI
severity. Furthermore, markers associated with the pathophysiol-
ogy of acute SCI should aid in monitoring the biological effects of
a candidate treatment and also may identify potential targets for
novel treatments that reduce secondary damage [5]. To date, few
studies have been conducted to identify biomarkers of SCI, and
most have investigated patients at risk of ischemic SCI after
surgery for thoracic and thoracoabdominal aortic aneurysms
(TAAAs), or after a nerve root compression in animal models [6].
Three studies have investigated biomarkers in traumatic animal
SCI models, and two examined cerebrospinal fluid (CSF) from
patients with traumatic SCI [7,8,9,10,11]. Collectively these
studies have identified S100 calcium binding protein beta
(S100ß), neuron specific enolase (NSE), neurofilament protein
(NFL), myelin basic protein (MBP), glial fibrillary acidic protein
(GFAP), the microtubule- associated tau proteins, monocyte
chemotactic protein 1 (MCP-1), and interleukins 6 and 8 (IL-6
and IL-8) as potential markers of spinal cord damage [6,11]. These
studies need to be extended, validated and developed for their
potential use in objectively determining the severity of SCI.
The goal of this study was to identify candidate biomarkers in
the CSF that could be evaluated for their utility in characterizing
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19247the severity of damage that occurs due to the primary mechanical
trauma. We used a preclinical rat model in which the spinal cord
injury is induced via a precisely controlled electro-mechanic
impactor. Due to its proximity to the CNS tissues we chose to look
for candidate SCI biomarkers in CSF, rather than in blood. The
application of liquid chromatography-mass spectrometry (LC-
MS/MS) combined with stable isotope labeling enabled us to
quantify changes in a large number of CSF proteins, yielding a
panel of 42 candidate biomarkers of SCI, including 10 biomarkers
that have the potential to distinguish between a moderate and
severe injury.
Materials and Methods
Ethics Statement
All animal procedures were performed in accordance with the
guidelines of the Canadian Council for Animal Care and
approved by the University of British Columbia animal care
committee (protocol # A09-0086).
Animals
In total, 108 male Sprague–Dawley rats (Charles River Breeding
Laboratories) 11–12 weeks old and weighing 350–420 g were used
for this study. All animals were maintained in a standard housing
environment with ad libitum access to food and water. Twenty seven
animals were used for behavioral and histological assessment of the
injury. A further 36 animals were used for CSF sample collection to
search for biomarkers by LC-MS/MS. In an additional cohort of
45 animals, CSF samples were collected for biomarker validation
by Western blot (WB). In all experiments the animals were
randomized and equally divided into three experimental groups: (1)
sham control, (2) moderate injury (1.3 mm displacement SCI) and
(3) severe (1.7 mm displacement SCI).
Surgery
Animals were anesthetized with an intraperitoneal (i.p.) injection
of ketamine (70 mg/kg) and rompun (10 mg/kg). After inducing a
surgical plane of anesthesia (end point of anesthesia was assessed by
toe pinch and eye blink reflex), the surgical area was shaved and
disinfected. The animal was placed in a stereotaxic apparatus (Kopf
Instruments, Tujunga, CA) and a dorsal midline incision was made
from C2 to C7. After the cervical vertebrae were carefully exposed
laminectomy was performed with fine rongeur at the C4/5 level to
expose the spinal cord. Following laminectomy, the spine was
stabilized by clamping the transverse processes of one segment
above and below the lesion site [12]. The contusion was generated
using the displacement-controlled OSU impactor (Ohio State
University, Columbus, Ohio) [13]. The impactor tip was centered
over the left side of the C4/5 and aligned at the grey/white matter
border. The contusion was done with displacement of 1.3 mm or
1.7 mm in the moderate and severe injury group, respectively. For
sham treatment, rats received a laminectomy followed by clamping
of the C3 and C5 transverse process and loading onto the impactor
device, but did not receive a SCI.
After surgery, the animals were kept in a temperature-controlled
incubator set at 32uC until they were completely awake.
Subcutaneous administration of 10 ml of Ringer’s-lactate solution
and buprenorphine (0.03 mg/kg) was given to prevent dehydra-
tion and post-operative pain.
Injury assessment
Initially 27 animals (sham: n=4, 1.3-mm: n=9, 1.7-mm:
n=14) were used for assessment of SCI severity. Behavioural
assessment of forelimb function was conducted 1 week prior to
injury and 1, 4, and 6 weeks after injury. To assess the overall level
of functional impairment, rats were examined for forelimb use
during vertical exploration in a cylinder [14,15,16]. On testing
days, rats were individually placed and videotaped in a clear
Plexiglas cylinder (20 cm in diameter and 30 cm high) for
265 minutes per session. Afterwards, the tapes were analyzed
frame-by-frame by an observer blinded to the randomized
treatment assignment of the animalsto determine forelimb usage
for contacting the wall of the cylinder during 20 independent
rears. During a rearing motion, the first forelimb to contact the
wall was scored as an either ‘‘left’’, ‘‘right’’, or ‘‘both’’ movement.
If an independent movement is followed by placement of the other
limb on the wall without first removing the first paw, this would be
scored as a subsequent ‘‘both’’ movement. After scoring a ‘‘both’’
movement, every additional combination of two-limb movements
received a subsequent ‘‘both’’ score. Forelimb usage was expressed
as percent use of the impaired paw (sum of left and both) relative
to the total wall placements.
At the end of the experiment (6–10 wks post-injury), animals
were perfused intra-cardially with 16PBS followed by 4%
paraformaldehyde. Cervical spinal cord were collected and post-
fixed overnight in 4% paraformaldehyde. After cryoprotection in
12%, 18% and 24% sucrose, spinal cords were frozen and cut in
20 mm thick cross-section on a cryostat (Microm, Heidelberg,
Germany). To visualize white and grey matter, coronal sections
through the cervical injury site were stained with Eriochrome–
cyanine (EC) as described previously [17]. Briefly, frozen spinal
cord sections were rehydrated and stained in EC Solution (0.16%
EC, 0.4% sulfuric acid and 0.4% ferric chloride) at room
temperature for 10 min. After a gentle rinse in dH2O, slides were
differentiated in 0.5% ferric ammonium sulfate at room
temperature for ,2 min., counterstained with 1% Neutral Red
and cover-slipped using Entallan mounting medium (EM Science,
Gibbstown, NJ). Images were captured with a bright-field
microscope (56 objective, Leica DM5000 B microscope, Leica
Microsystems). The section with the least amount of white matter
sparing was defined as the lesion epicenter.
For the cohort of animals used in biomarker discovery and
validation the actual force delivered was recorded for each impact
which, in combination with a visual inspection (that shows a
hematoma), allowed the surgeon to confirm the impact. Criteria
for the force curves were set and any spikes (bone hits) or unusual
force clips (indicative of slippage) would lead to exclusion of the
animal from the study. Recorded force of impact was also used to
assess injury severity and animals that received an impact with
recorded force outside the range of 150–161 Kdynes for moderate
injury or 165–176 Kdynes for severe injury were excluded from
the study. Using these criteria seven animals were removed from
the biomarker study after injury because of either insufficient or
excessive severity. Two animals did not wake up from anesthesia.
Thus, 32 and 40 animals were used for sample collection for LC-
MS/MS and Western blot analyses, respectively.
Cerebrospinal fluid (CSF) collection
CSF was collected by puncture of the cisterna magna 24 h after
injury. To minimize protein degradation in tissues, anesthetized
rats were perfused intracardially with 100 ml of ice cold PBS prior
to CSF collection and were kept on ice during sample collection.
CSF was visually inspected for the presence of blood contamina-
tion and contaminated samples were excluded from further
analysis (5 CSF samples from LC-MS/MS analysis and 4 samples
from WB analysis) leaving samples from 27 animals for LC-MS/
MS analysis and 36 animals for WB analysis. CSF samples were
centrifuged at 6,0006ga t4 uC to remove cellular debris. Protease
Biomarkers of Spinal Cord Injury
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Diagnostics Canada, Laval, Quebec) were added to the pre-
cleared CSF and the samples were frozen at 280uC.
Protein preparation for mass spectrometry (MS)
For MS analysis, CSF was thawed on ice and all samples within
each treatment group were combined to give a single pooled CSF
sample for each treatment (Figure 1). The protein concentration of
each pooled CSF sample was determined using EZQ Protein
Quantitation kit (Molecular Probes, Eugene, OR) and aliquots
containing 25 mg of protein were precipitated using the ethanol/
acetate method [18]. The precipitated protein pellet was air-dried
and re-dissolved in 30 ml of trypsin digestion buffer (1% sodium
deoxycholate, 50 mM NH4HCO3) for MS analysis.
The protein samples were denatured for 5 min at 99uC,
reduced with 0.5 mg Dithiothreitol (DTT) for 30 min at 37uC,
alkylated with 2.5 mg iodoacetamide (20 min at 37uC), and
digested with 0.5 mg trypsin (overnight at 37uC). Following
digestion, peptides were desalted using C18STop And Go
Extraction (STAGE) tips (made ‘‘in-house’’) [19]. Next, the
peptides from CSF of animals after sham, moderate, and severe
injury were labeled with light (CH2O), medium (CD2O), and
heavy (
13CD2O) isotopologues of formaldehyde, respectively [20].
The use of different labels enabled mixing of peptides from CSF of
animals after sham, moderate and severe injury and simultaneous
sample processing and analysis, thus eliminating artificial differ-
ences due to between run variability. The labeled peptides were
then fractionated on C18-SCX-C18 STAGE tips using a 5-step
ammonium acetate elution gradient [21] and the dried peptide
fractions were resuspended in 1% trifluoroacetic acid, 3%
acetonitrile, and 0.5% acetic acid.
Liquid chromatography-mass spectrometry (LC-MS/MS)
The peptide fractions were analyzed on a linear trapping
quadrupole-OrbitrapXL hybrid mass spectrometer (Thermo-
Fisher Scientific, Waltham, MA, USA) as previously described
[22]. The LTQ-OrbitrapXL was on-line coupled to an 1100
Series nanoflow HPLC (Agilent Technologies, Santa Clara, CA)
using a nanospray ionization source (ProxeonBiosystems, Odense,
Denmark) holding columns packed into 15-cm-long, 75-mm-inner
diameter fused silica emitters (8-mm-diameter opening, pulled on a
P-2000 laser puller from Sutter Instruments) using 3-mm-diameter
ReproSilPur C18 beads. Buffer A consisted of 0.5% acetic acid,
and buffer B consisted of 0.5% acetic acid and 80% acetonitrile.
Gradients were run from 6% B to 30% B over 90 min, then 30%
B to 80% B in the next 10 min, held at 80% B for 5 min, and then
dropped to 6% B for another 15 min to recondition the column.
The mass spectrometer was set to acquire a full-range scan at
60,000 resolution from 350 to 1500 Thomson (Th) units in the
Orbitrap and to simultaneously fragment the top five peptide ions
in each cycle in the LTQ. Fragment spectra of multiply charged
ions were then searched against the Rat International Protein
Index database with reversed sequences concatenated onto it
(v3.47, 80,285 sequences) using MASCOT v2.2 (Matrix Science,
London). The following search parameters were used in all
MASCOT searches: trypsin (allowing up to one missed cleavage)
or no enzyme specificity (in separate searches); carbamidomethyl
as a fixed modification, variable modifications of dimethylation by
both hydrogen isotopes at the peptides’ amino termini and lysine
e-amino groups, 10 ppm peptide tolerance; 0.8 daltons (Da)
fragment ion tolerance, and electrospray ionization-Trap frag-
mentation characteristics. All identified peptides were first
recalibrated using MSQuant [23] and then only proteins with at
Figure 1. Experimental Outline.
doi:10.1371/journal.pone.0019247.g001
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and an absolute calibrated mass error of ,5 ppm were considered
identified. The false discovery rate for this dataset, estimated at
,1%, was calculated by dividing the sequence-reversed proteins
that failed to be eliminated after applying the above criteria.
Results from multiple experiments were combined at the peptide
level and then recombined into a final, non-redundant list of
identified proteins. Chromatographic peak areas for the formal-
dehyde isotopologues (light, medium and heavy) of each detected
peptide were first extracted using MSQuant [23] and then
manually inspected to correct errors from overlapping peaks,
missed monoisotopic peaks, etc. Only proteins for which a
quantitative ratio was detected in at least two experiments were
considered further. Peptides matching to multiple known iso-
forms/splice variants were retained and used for quantifying in
each instance.
Western Blotting
CSF samples from four rats in each treatment group were
pooled randomly to obtain sufficient protein for analysis. This
sample pooling created three CSF samples for each treatment (C1,
C2, C3 – sham; M1, M2, M3 – moderate injury; S1, S2, S3 –
severe injury). Twenty micrograms of total protein was resus-
pended in 16sodium dodecyl sulfate (SDS) buffer (62.5 mMTris–
HCl, pH 6.8, 10% glycerol, 2% SDS, 5% 0.1 M DTT, 0.05%
bromophenol blue), loaded on a 12% or 7% SDS-polyacrylamide
gel and resolved by electrophoresis at 90 V (4uC). Proteins were
electrotransfered to a 0.5 mm nitrocellulose membranes at a
constant current of 180 mA for 60 min in 4uC. For S100a8
immunobloting, proteins were separated on 18% gel and the WB
was done essentially as described in Coorssen et al [24], except
that myoglobin was not added to the protein sample or the gel
equilibrating buffer. Membrane washing and protein detection
were done according to manufacturer’s recommendations for the
Odyssey and IRDye system (LI-COR Biosciences, Lincoln,
Nebraska), and the following antibodies were used at 1:200
dilution: Ywhaz (Abcam, #ab32622), Gpx3 (Abcam, #ab59524),
S100a8 (Santa Cruz, #sc-8113), Itih4 (Santa Cruz, #sc-34471),
and Trf (Santa Cruz, #sc-22597).
Ingenuity Pathways Analysis
The functional analyses were generated through the use of
Ingenuity Pathways Analysis (IPA) v7.6 (www.ingenuity.com). For
this analysis the average relative protein ratios obtained from MS
analysis are converted to fold change values by the IPA software.
The data set was filtered for proteins present in CSF only, and
proteins from the filtered dataset that met the fold change cut-off
of 1.5, and were associated with biological functions in the
Ingenuity Pathways Knowledge Base, were considered for the
analysis. The IPA uses right-tailed Fischer’s exact test to calculate
a p-value determining the probability that each biological function
assigned to that data set is due to random chance alone. The p-
value for a given function is calculated by considering the number
of proteins in the dataset that participate in that function and the
total number of molecules that are known to be associated with
that function in the IPA knowledge base. P-values,0.05 were
considered statistically significant, non-random associations.
Results
Our objective was to create a unilateral cervical contusion
injury with defined tissue displacements (1.3 and 1.7 mm) to
produce injuries of graded severity (‘‘moderate and ‘‘severe’’). Rats
receiving contusion injuries targeted at C4/C5 with displacement
set to 1.3-mm yielded an average force recording of 155.765.0
Kdynes. An average force of 170.665.0 Kdynes was reached with
a displacement setting of 1.7 mm. Preoperatively, non-contused
(sham) animals and rats from the moderate (1.3-mm) and severe
(1.7-mm) injury groups performed equally well (Figure 2a) and
used their impaired forelimb either independently or in combina-
tion with the contralateral paw ,70% of total wall placements
made (forelimb usage sham: 71.966.1%, moderate: 70.665.6%,
severe: 73.262.1%). Postoperatively, animals from both the
moderate and severe injury group were significantly different
compared to non-contused sham controls during the 6 week time
period they were observed (ANOVA repeated measures with
Bonferroni correction, moderate: p=0.032, severe: p=0.0001,
Figure 2a). Group comparison per week (One-way ANOVA)
revealed that the moderate injury produced forelimb deficits at
weeks 1 and 4 after injury (wk1: 42.268.8%; wk4: 45.466.9%)
compared to sham animals (wk1: 83.966.9%, p=0.001; wk4:
72.862.6%, p=0.02). However, the animals did recover over
time resulting in an average forelimb usage of 51.868.0% at 6
week following injury (sham: 70.167.5, p=0.0413). The severe
injury group was significantly different from both sham and
moderate injury animals at any time point following injury and
only used their impaired forelimb during ,10% of the total
placements made (wk1: 11.763.8%; wk4: 9.463.4%; wk6:
13.064.7%).
Coronal sections of the spinal cord taken from animals receiving
either moderate or severe displacement injuries are shown in
Figure 2b. At the epicentre, the moderate displacement injury
mostly encompassed the grey matter, with the exception of a small
rim of spared tissue of the dorsal horn. Only minimal ipsilateral
white matter damage was detected to the ventrolateral, lateral, and
dorsolateral funiculus. The severe injury group showed severe
damage of ipsilateral white matter compared to the moderate
injury group and with only a small rim of spared white matter of
the ventrolateral and dorsal funiculus. The severe displacement
injury completely destroyed the dorsal and ventral horns at the
epicentre.
In order to quantify changes in protein composition in the rat
CSF 24 hours after SCI, we applied quantitative proteomics using
stable isotope labeling and LC-MS/MS. This proteomic approach
allowed for simultaneous analysis of CSF from sham, moderate,
and severe injury groups. Prior to LC-MS/MS analyses the CSF
samples were fractionated by strong cation exchange (SCX) to
decrease the complexity of CSF samples. Due to the low volume of
CSF obtained from a single animal (50–80 ml) and the relatively
low protein concentration in the CSF (0.2–0.8 mg/ml), the samples
in each treatment group were pooled to attain sufficient protein for
subsequent fractionation and MS analysis.
Each pooled sample was split into 3 aliquots and analyzed by
LC-MS/MS on separate days. The LC-MS/MS identified 2,924
peptides (Table S1), which after applying the cut-off criteria (see
Materials and Methods), resulted in identification of 334 proteins
in the rat CSF (Table S2). Of these 334 proteins, 146 were
consistently quantifiable across at least two MS runs and are
presented as moderate injury/sham and severe injury/sham ratios
(Table S3, Figure 3).
Potential biomarkers of SCI were defined using a cut-off ratio of
more than 2.0 or less than 0.5. Using this cut off, 42 potential
biomarkers of SCI were identified (Tables 1,2, 3, 4). Proteins that
showed at least a 2-fold difference in ratio between the moderate
and severe injury models were defined as putative biomarkers of
SCI severity. Using these selection criteria, 10 of the 42 candidate
biomarkers appeared to distinguish between moderate and severe
SCI (Tables 3 and 4, Figure 3).
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of severity, and antibody availability, we selected four proteins for
validation by Western blot analysis: Ywhaz; Gpx3; Itih4; and
S100a8. Serotransferrin (Tfr, IPI00679202), which was not
affected by the injury in LC-MS/MS analysis, was included in
the Western blot analysis as a control. For this analysis the animal
injury experiments were repeated and CSF was collected. The
limited amount of CSF obtained from a single rat prevented
analysis of individual CSF samples. However, to obtain some
information about the degree of variability within each injury
group the CSF samples were pooled randomly to create three
independent CSF samples for each injury group. The western blot
results confirmed the MS data for all of the proteins, except for
S100a8 (Figure 4). S100a8 was not detectable in CSF by WB even
though it was detected in a spleen sample, which was run in
parallel as a positive control. We observed some degree of
variability in the proteins levels between the CSF samples within
each injury group. However, the overall trend in protein change
was conserved, with all three proteins showing increased levels
after injury (Figure 4b). Furthermore, there was a significant
difference in the Ywhaz and Itih4 protein levels between moderate
and severe injury groups, confirming their potential to serve as
markers of injury severity (Figure 4b quantification pane).
To determine if molecular and cellular processes are differen-
tially affected in the moderate vs. severe models of SCI, we
analyzed our LC-MS/MS data set using the ‘‘Core analysis’’
module of the IPA software. The IPA program facilitates the
interpretation of expressiondata in the contextof biologicalsystems
by associating the set of differentially expressed genes with known
(experimentally demonstrated) biological relationships. For this
analysis we used the ‘‘CSF fluid’’ as the dataset filter and a 1.5-fold
change in protein abundance as a cut-off value. In the context of a
biological system, modest changes in the levels of a large number of
proteins involved in a particular pathway or biological process may
be more meaningful than large changes in a small number of
proteins. This was the rationale for selecting less stringent cut off
values for the IPA analyses (1.5-fold for the IPA vs. 2.0-fold for the
identification of potential biomarkers of SCI). Using this selection
criteria a total of 76 CSF proteins were consistently affected by SCI.
Although comparison of the IPA functional analyses of moderate
and severe injury data sets indicates that many molecular and
cellular processes are significantly (p,0.05) affected in both injury
models, proteins involved in cellular and molecular functions such
as cell morphology, cell signaling, antigen presentation, molecular
transport, and vitamin and mineral metabolism were associated
more significantly with the moderate injury data set (Figure 5).
Whereas, changes in the abundance of proteins associated with
cellular movement, development, macromolecular assembly,
cellular organization, cell death, small molecule biochemistry,
and amino acid and lipid metabolism were more evident in the
severe injury data set.
Discussion
To find biomarkers of SCI severity we used a standardized rat
injury model in which an electro-mechanic impactor strikes the
spinal cord and displaces it to a specific extent. This allowed us to
define the severity of injury (moderate vs. severe injury) and
resulted in a reasonable consistency of injury within each cohort of
test animals. Through LC-MS/MS analyses of labeled CSF
peptides we identified a total of 42 proteins that are potential
biomarkers of spinal cord injury. Importantly, 10 of these proteins
allow one to distinguish between moderate and severe SCI events.
Western blot analyses confirmed the MS results for Gpx3, a
potential SCI biomarker, and two potential markers of SCI
severity, the Itih4 and Ywhaz.
Figure 2. Injury assessment. (A) Influence of 1.3-mm and 1.7-mm displacement injuries at C5 on forelimb usage during rearing. A contusion injury
with a tissue displacement of 1.3-mm produced a ‘mild’ injury with forelimb motor deficits that recovered over time. The more ‘severe’ 1.7-mm
displacement injury produced nearly complete loss of forelimb usage that was sustained until the end of the study. Error bars indicate standard error
of the mean (SEM). ‘‘*’’ significantly different from sham group, p#0.05; # 1.7-mm groups significantly different from 1.3-mm group, p#0.05. (B)
Histological outcome to the spinal cord following contusion injury with 1.3-mm or 1.7-mm tissue displacement 6–10 weeks after injury. Example
image of eriochrome cyanine- and neutral red-stained coronal section of the injury at the epicenter. Scale bar: 500 mm.
doi:10.1371/journal.pone.0019247.g002
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A2M, C3, ApoA1, ApoH, and Ambp, are present among the
potential SCI biomarkers identified in our study. The immune
proteins are often thought to be plasma-derived proteins, and one
might argue that their presence in the CSF following SCI may be
due to leakage through the blood-CNS barrier. However, the fact
that higher levels of these proteins are present in the moderate
injury CSF, where there is less damage to the blood-CNS barrier,
argues against plasma leakage as a source of these proteins in CSF.
Moreover, the absence of ApoB, which is not normally present in
Figure 3. Quantitative proteomic analysis of CSF from injured animals. (a) Relative protein abundances for all proteins detected in rat CSF
24 h after sham, moderate or severe SCI. Labeled data points represent potential biomarkers of SCI severity (Tables 3 and 4). Error bars represent
standard error of the mean (SEM). (b) Representative examples of MS spectra from the indicated peptides. Open arrowheads point to the
monoisotopic peaks from light (sham), medium (moderate) and heavy (severe) conditions.
doi:10.1371/journal.pone.0019247.g003
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Protein ID Protein Description Protein Symbol Moderate/sham Severe/sham Gene Ontology
AVG ratios SEM AVG ratios SEM
1 IPI00781399 Immunoglobulin
heavy chain 1a
LOC678701 2.9 0.20 1.9 0.22 rat plasma protein; immune response
2 IPI00324893 14-3-3 protein zeta/delta Ywhaz 2.8 0.31 3.5 0.40 histamine secretion; protein targeting to
mitochondrion; response to drug
3 IPI00568389 similar to NGF-binding
Ig light chain
LOC500183 2.8 0.45 1.8 0.38 Immune response
4 IPI00188338 inter-alpha-trypsin
inhibitor 1
Itih1 2.7 0.22 2.0 0.31 hyaluronan metabolism, leukocyte
activation
5 IPI00197703 Apolipoprotein A-I Apoa1 2.6 0.15 1.8 0.28 signal transduction; adrenal gland
development; axon regeneration;
endothelial cell migration and
proliferation; cholesterol transport and
metabolism; glucocorticoid metabolic
process; lipid storage and metabolism;
lipoprotein metabolic processes; negative
regulation of cytokine secretion;
regulation of hydrolase activity;
regulation of lipoprotein remodeling;
organ regeneration; phosphatidylcholine
biosynthetic process; phospholipid
transport and metabolism; regulation of
transferase activity; protein stabilization;
regulation of amino acid
phosphorylation; response to drug;
steroid metabolic process; response to
estrogen stimulu
6 IPI00372372 Serine (Or cysteine)
peptidase inhibitor
C1 (Antithrombin)
Serpinc1 2.6 0.42 1.7 0.35 negative regulation of inflammatory
response; response to nutrient
7 IPI00210900 alpha-1-microglobulin/
bikunin precursor
Ambp 2.4 0.18 1.7 0.28 protein-chromophore linkage; transport;
cell adhesion; pregnancy; heme catabolic
process; interspecies interaction; negative
regulation of JNK cascade; negative
regulation of immune response
8 IPI00389806 similar to inter-alpha-
inhibitor H2 chain
LOC498793 2.3 0.11 1.8 0.24 serine protease inhibitor activity;
hyaluronan metabolism
9 IPI00565114 Junctional adhesion
molecule 2 (13 kDa protein)
Jam2 2.2 0.21 1.6 0.28 Cell-cell adhesion; (may be involved in
maintenance of stem cell identity)
10 IPI00559019 similar to Igk 13 kDa protein 2.2 0.25 2.0 0.31 immune response
11 IPI00188225 C-reactive protein Crp 2.1 0.14 1.6 0.28 acute-phase response; complement
activation (classical pathway); negative
regulation of foam cell differentiation;
negative regulation of lipid storage;
transport
12 IPI00231783 L-lactate dehydrogenase
Bc h a i n
Ldhb 2.0 0.24 2.4 0.35 NAD metabolic process; anaerobic
glycolysis; cellular carbohydrate
metabolic process; lactate metabolic
process; oxidation reduction
13 IPI00778633 Apolipoprotein H Apoh 2.0 0.22 1.6 0.28 blood coagulation; negative regulation of
angiogenesis; negative regulation of
endothelial cell migration and
proliferation; negative regulation of
fibrinolysis; negative regulation of myeloid
and smooth muscle cell apoptosis; organ
regeneration; plasminogen activation;
positive regulation of lipoprotein lipase
activity; triglyceride transport and
metabolic process
14 IPI00191139 Secretogranin-3 Scg3 0.7 0.06 0.4 0.15 not annotated
15 IPI00388323 heparan sulfate
proteoglycan 2
Hspg2 0.6 0.08 0.4 0.09 embryo implantation; negative regulation
of cell adhesion; regulation of cell
proliferation; organ regeneration;
response to drug; response to hypoxia
16 IPI00331757 FAM3C-like protein Fam3c 0.6 0.12 0.5 0.17 not annotated
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leakage from plasma an unlikely source for the increased
abundance of immune proteins in our experiments.
The observation that the relative abundance of some of these
proteins is higher among those animals with moderate injury
than it is among those with severe injury seems somewhat
counterintuitive. However, many of these proteins, including
Apoa1 [26], Serpinc1 [27], Ambp [28], A2M [29] are negative
regulators of the immune response. Since cells in damaged tissue
must choose one of two options: either cellular repair or cellar
elimination, we speculate that in moderate injury, many of the
cells engage the cellular repair pathway, and suppression of some
components of the immune response would be consistent with
this process. If that were true, one might predict that proteins
that stimulate the immune response would be up-regulated
among those animals that experienced a severe SCI event.
Indeed, two of the proteins that were up-regulated in the severely
injured animals, S100a8 and B2M, are known to function as
positive regulators of the immune response [30,31]. Interestingly,
Khwaja et al [32] recently reported a similar observation in
patients with brain tumors. They noted that many immune
response proteins were elevated in the CSF from patients with
lower grade astrocytoma but were absent from CSF of patients
with high-grade tumors.
The levels of two antioxidant enzymes, Gpx3 and Prdx2, were
considerably higher in the CSF of animals that had suffered a
moderate SCI as compared to those animals that had a severe
SCI. Furthermore, Prdx2 levels were down-regulated in severe
and up-regulated in moderate injury group as compared to sham.
This suggests that the cellular anti-oxidant response mechanisms
may be weaker among animals that were subjected to severe SCI.
This finding is particularly interesting, since oxidative stress is a
well documented mechanism of secondary injury following
traumatic SCI [33,34,35]. If this is true, then the oxidative stress
response mechanism may provide an interesting therapeutic
target, since the reduction in the level of oxidative stress may
effectively reduce some of the protein turnover within the cells. In
turn, this may reduce the progression of the secondary damage
that normally accompanies SCI, and thus enhance neurological
recovery.
The identification of two 14-3-3 proteins, Ywhaz and Ywhag,
among the potential SCI biomarkers came as no surprise. The 14-
3-3 proteins are ubiquitously expressed, with their highest levels
found in CNS tissues. These proteins are able to bind a multitude
of different signaling proteins including kinases, phosphatases and
transmembrane receptors and play a major role in modulating a
wide range of regulatory processes such as mitogenic signal
transduction, cell cycle control, ion channel regulation, and
apoptosis [36]. Elevated levels of the 14-3-3 proteins in the CSF
are associated with acute brain injury [37], dementia [38],
Creutzfeldt-Jakob disease [39], and motor neuron injury [40].
Therefore, it is quite likely that their elevated levels following SCI
reflect the process of neuronal damage [39]. With the exception of
slightly higher levels of Ywhaz in the CSF after severe injury as
compared to moderate injury (a finding confirmed by western
blot), we did not observe a significant difference in protein levels of
these two 14-3-3 proteins between the two injury models. Taken
together, these two observations suggest that elevated levels of
Ywhaz and Ywhag proteins may be useful as general markers of
neuronal injury, including SCI, but their levels do not distinguish
differing severities of injury.
It is worth noting the presence of three inter-alpha-trypsin
inhibitors (Itih1, Itih3, and Itih4) in our panel of candidate
biomarkers of SCI. In addition, ITIH4 is a potential biomarker for
the severity of SCI. The ITIs are a family of structurally related
plasma serine protease inhibitors that are involved in extracellular
matrix stabilization and the inflammatory response [41]. They
have been shown to bind hyaluronan (HA), a glycosaminoglycan
(GAG), which is an integral component of the CNS extracellular
matrix and thus modulate the levels of free HA [42]. Free HA
accumulates in the extracellular matrix of damaged CNS [43,44]
and may contribute to the inhibition of re-myelination and axonal
regeneration during CNS repair due to its influence on neural
stem/progenitor cell differentiation, astrocyte proliferation and
Protein ID Protein Description Protein Symbol Moderate/sham Severe/sham Gene Ontology
AVG ratios SEM AVG ratios SEM
17 IPI00197041 Neuroblastoma suppressor
of tumorigenicity 1
Nbl1 0.6 0.11 0.5 0.14 down-regulated in transformed cells
(possible tumor suppressor)
18 IPI00392886 Alpha-2-macroglobulin A2m 2.1 0.16 1.1 0.22 acute-phase response; inflammatory
response; negative regulation of
complement activation (lectin pathway);
response to chemical stimulus; response
to glucocorticoid stimulus; response to
nutrient; response to wounding
19 IPI00679245 T-kininogen 2 MGC108747 2.0 0.13 1.1 0.20 acute-phase response; vasodilation
20 IPI00480639 Complement C3 C3 2.0 0.23 1.3 0.23 blood coagulation; complement
activation; inflammatory response;
positive regulation of phagocytosis;
positive regulation of type IIa
hypersensitivity
21 IPI00204359 Beta-2-microglobulin B2m 0.5 0.18 0.9 0.24 antigen processing and presentation;
positive regulation of T cell mediated
cytotoxicity; response to cadmium ion;
response to drug
Proteins consistently changed across three LC-MS/MS runs.
Potential biomarkers were selected based on average ratio $2.0 or #0.5. AVG – average; SEM – standard error of the mean.
doi:10.1371/journal.pone.0019247.t001
Table 1. Cont.
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outgrowth and the onset of inflammation [45]. Hence higher levels
of inter-alpha-antitrypsin inhibitors in the moderate injury CSF
may reduce the amount of free HA and limit its inhibitory effect
on spinal cord repair. Accordingly, this may suggest a pathway,
and thus potential targets, for the development of compounds that
suppress this inhibitory process.
The S100ß and NSE proteins were previously reported as
potential biomarkers of traumatic SCI in rat [8,9]. However, we
did not find any significant alterations in the relative abundance of
these proteins in our experiments. Of course, it is possible that
both of these proteins are elevated within the first few hours of
SCI, with levels peaking at 6 h post injury and are not detectable
after 24 hours in rats [8,9]. This appears to be the case also in
patients that receive thoracic endovascular stent grafting to treat
thoracic and thoracoabdominal aortic aneurysms (TAAAs), a
procedure associated with an increased risk of ischemic spinal cord
damage [46,47]. However, our LC-MS/MS analyses did identify
another member of the S100 family of calcium binding proteins,
S100a8, and its level appears to be correlated with the severity of
SCI. Our attempt to confirm this result by WB was unsuccessful,
possibly because the S100a8 levels were too low to be detected by
WB analyses using this particular antibody. The S100a8 protein
belongs to the S100 family of proteins involved in the regulation of
Table 2. Potential biomarkers of SCI identified by quantitative LC-MS/MS analysis of CSF from rats following experimental SCI.
Protein ID Protein Description
Protein
symbol Run 1 ratios (±SD) Run 2 ratios (±SD)
Average
ratios Gene Ontology
M/S S/S M/S S/S M/S S/S
1 IPI00230835 14-3-3 protein gamma Ywhag 4.46±07 . 1 ±0 6.06±03 . 5 ±0 5.3 5.3 protein targeting; neuron
differentiation; synaptic plasticity;
signal transduction
2 IPI00515829 Kininogen 1 Kng1 3.33±0 2.05±0 3.27±0 2.99±0 3.3 2.5 elevation of cytosolic Ca
2+; MAP
kinase activity; coagulation; cell
adhesion; lymphocyte proliferation;
proteolysis; MAPKKK cascade;
endothelial cell proliferation;
fibroblast proliferation;
endopeptidase activity
3 IPI00204451 Complement factor I Cfi 1.45±0.19 1.77±0.46 2.81±1.24 2.25±0.46 2.1 2.0 complement activation; innate
immune response; proteolysis
4 IPI00391528 Similar to
immunoglobulin Kappa
light chain V gene
13 kDa
protein
2.36±0 1.82±0 1.66±0 1.09 2.0 1.5 immune response
5 IPI00189981 Prothrombin (Fragment) F2 1.98±1.15 2.59±0 1.97±0 0.57±0.2 2.0 1.6 acute phase response; coagulation;
cell surface receptor linked signal
transduction; cytosolic Ca
2+
homeostasis; fibrinolysis; platelet
activation; collagen biosynthetic
process; protein amino acid
phosphorylation; proteolysis;
response to stress; wound healing
6 IPI00326984 Inter-alpha-trypsin
inhibitor heavy chain H3
Itih3 1.84±0.52 1.73±0.25 2.11±0.57 1.01±0.38 2.0 1.4 hyaluronan metabolic process
7 IPI00568410 Protein kinase
C-binding protein
Nell2 0.87±0 0.26±0 0.59±0 0.59±0 0.7 0.4 cell adhesion; regulation of growth
8 IPI00200257 T-cadherin Cdh13 0.57±0 0.28±0 0.77±0 0.56±0 0.7 0.4 Rac protein signal transduction; Rho
protein signal transduction; LDL-
mediated signaling; EGFR signaling
pathway; cell adhesion; cell growth
and proliferation; calcium-mediated
signaling; cell migration; chemotaxis;
survival gene product expression;
endocytosis; response to organic
substance; sprouting; angiogenesis
9 IPI00209114 Isoform 1 of Limbic
system-associated
membrane protein
Lsamp 0.77±0 0.46±0 0.53±0 0.45±0 0.7 0.5 cell adhesion; nervous system
development
10 IPI00199030 Neuroendocrine
protein 7B2
Scg5 0.51±0 0.52±0 0.47±0.07 0.36±0.03 0.5 0.4 intracellular protein transport;
neuropeptide signaling pathway;
peptide hormon processing;
regulation of hormone secretion;
transport
11 IPI00391338 Similar to ICOS
ligand precursor
Icosl 1.12±0 0.39±0 0.59±0 0.63±0 0.9 0.5 positive regulation of interleukin-4
biosynthetic process
Proteins consistently changed across two LC-MS/MS runs.
Potential biomarkers were selected based on average ratio $2.0 or #0.5. SD – standard deviation. M/S – moderate/sham ratio; S/S – severe/sham ratio.
doi:10.1371/journal.pone.0019247.t002
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SCI.
Protein ID Protein Description Protein Symbol Moderate/sham Severe/sham Gene Ontology
AVG ratios SEM AVG ratios SEM
1 IPI00188541 Inter-alpha-inhibitor
H4 heavy chain
Itih4 4.5 0.41 1.8 0.33 hyaluronan metabolic process;
acute phase response
2 IPI00476458 Glutathione peroxidase 3 Gpx3 4.2 0.30 1.9 0.27 glutathione metabolic process;
hydrogen peroxide catabolic
process; oxidation reduction;
protein homotetramerization;
response to oxidative stress
3 IPI00326140 Pregnancy zone protein Pzp 3.9 0.41 2.1 0.36 pregnancy
4 IPI00360930 Carbonic anhydrase 1 Car1 2.4 0.21 0.4 0.12 one-carbon metabolic process
5 IPI00207146 Zero beta-1 globin MGC72973 6.1 0.78 1.0 0.31 oxygen transport
6 IPI00191715 Alpha-1-acid glycoprotein Orm1 2.1 0.18 0.9 0.21 acute-phase response; regulation
of immune system process
Proteins consistently changed across three LC-MS/MS runs.
Selection of potential biomarkers of SCI severity was based on more than two-fold difference in the average ratio between the two injury models. AVG – average; SEM –
standard error of the mean.
doi:10.1371/journal.pone.0019247.t003
Table 4. Potential biomarkers of SCI severity identified by quantitative LC-MS/MS analysis of CSF from rats following experimental
SCI.
Protein ID Protein Description Protein Symbol Run 1 ratios (±SD) Run 2 ratios (±SD)
Average
ratios Gene Ontology
M/S S/S M/S S/S M/S S/S
1 IPI00231370 Protein S100-A8 S100a8 5.32±0 11.8±0 0.95±0.68 3.31±2 3.1 7.6 Chemotaxis; inflammatory
response
2 IPI00201561 Peroxiredoxin-2 Prdx2 3.08±0.13 0.36±0.11 2.45±1.61 0.44±0.19 2.8 0.4 T cell proliferation and
differentiation; activation of
MAPK activity; anti-apoptosis;
cell homeostasis; hydrogen
peroxide metabolism;
negative regulation of NFkB
activity; lipopolysaccharide-
mediated signaling pathway;
neuron apoptosis; respiratory
burst during acute
inflammatory response;
response to oxidative stress;
thymus development
3 IPI00230787 Carbonic anhydrase 2 Car2 2.53±0 0.76±0 2.60±0 0.41±0 2.6 0.6 CO2 transport; kidney
development; epithelium
morphogenesis;
odontogenesis; one-carbon
metabolic process; osteoclast
differentiation; bone
resorption; regulation of
cellular pH; response to
steroid hormone stimulus;
response to stress; response
to zinc ion; secretion
4 IPI00558944 RGD1564861 similar
to Ig variable region,
light chain
RGD1564861 1.28±0 3.32±0 2.00±0.1 4.86±0.11 1.6 4.1 rat plasma protein; immune
response
Proteins consistently changed across two LC-MS/MS runs.
Selection of potential biomarkers of SCI severity was based on more than two-fold difference in the average ratio between the two injury models. SD – standard
deviation; M/S – moderate/sham ratio; S/S – severe/sham ratio.
doi:10.1371/journal.pone.0019247.t004
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diverse cellular and molecular processes including protein
phosphorylation, transcription, cell-cycle regulation, cell growth,
motility, differentiation and survival, as well as, inflammation
[30][47]. Hence, even though we were unable to validate this
potential biomarker of SCI severity by WB, we feel that this
protein needs to be investigated further, with more extensive
sample pre-fractionation prior to quantification.
Applying the Ingenuity Pathways Analysis (IPA) to the LC-MS/
MS data revealed a differential effect on several molecular and
cellular processes in the two SCI injury models. Interestingly,
changes in protein levels within the severe injury data set showed a
stronger association with cellular processes such as cell movement,
development, assembly, organization, and death. This association
was primarily due to down-regulation of several proteins involved
in these processes, suggesting a shutdown of cellular functions.
Among these proteins Prdx2, Ncam1, and Chl1 have also been
shown to decrease neuronal cell death [48,49,50]. Furthermore
IPA analyses indicated that some metabolic processes are also
differentially affected in the two injury models, with the moderate
injury dataset showing stronger association with calcium transport
and calcium efflux/influx, and the severe injury dataset being
more significantly associated with lipid metabolism. Lipid signaling
plays a crucial role in the development, differentiation, function,
protection, and repair of the CNS and deregulation of lipid
metabolism is believed to be a key event in neurodegenerative
disorders and CNS injuries such as stroke [51]. Loss of
intracellular calcium homeostasis is also a contributing factor in
the development of neurodegenerative disorders and CNS injuries,
including stroke and SCI, and an imbalance in calcium handling
can intensify the susceptibility of neural tissue to oxidative stress
and can lead to mitochondrial dysfunction resulting in cell death
[51,52].
LC-MS/MS analysis of CSF protein levels after SCI generated
a panel of potential biomarkers of SCI, including a set of markers
that may help to distinguish between moderate vs. severe SCI
events. One limitation of this study was the small amount of CSF
obtained from a single rat, which prevented the analysis of
individual animals to determine the degree of inter-individual
variability in the proteins levels following injury. Notwithstanding
the need for sample pooling, our data provides support for the
hypothesis that differences in protein levels may reflect the severity
Figure 4. Western blot validation of candidate biomarkers of spinal cord injury. (a) pooled sample of CSF from 12 sham injury rats (C);
pooled sample of CSF from 12 moderate injury rats (M); pooled sample of CSF from 12 severely injured rats (S). The chart on the right shows
quantification of the Western blots of moderately and severely injured rats relative to sham injury, (b) three pools of CSF from four sham, moderate
and severe injury rats, C1–C3, M1–M3, S1–S3, respectively. The chart on the right shows quantification of the Western blots relative to sham injury.
Each data point represents mean of three samples; error bars – standard error of the mean.
doi:10.1371/journal.pone.0019247.g004
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to determine the severity of SCI and allow neurological prognosis.
Another limitation of the study is the presence of only one time
point for the collection of CSF after spinal cord injury. Inclusion of
additional time points would provide more information about the
role of identified putative markers in the secondary spinal cord
damage. Also, given the complex and dynamic pathology of SCI,
it can be expected that the levels of biomarkers of spinal cord
damage will be time dependent, and thus an accurate assessment
of the severity of the injury will require a marker that is stably
altered during the acute phase of SCI. More likely, a panel of
several markers potentially at different times post-injury will
provide a better correlation with injury severity. However, the
main goal of this study was to determine the feasibility of
employing mass spectrometry to detect biomarkers of SCI and
further, whether this technique could reveal objective biomarkers
of the severity of SCI, hence we only examined one time point.
Since we detected 42 potential biomarkers, ten of which may
distinguish injury severity, we believe the method has been
confirmed. Initially, we chose the 24 hour post-injury collection of
CSF because it is a time point at which it will be feasible to obtain
CSF from injured patients – many of whom arrive at the hospital
from hundreds of miles away. Future studies will undoubtedly
canvas several post-injury time points which, in addition to
providing biomarkers of SCI, will provide insight into the repair
mechanisms, provide targets for therapeutic intervention and
allow monitoring of patient recovery.
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